The Ontario Perinatal Record (OPR) replaces the Ontario Antenatal Record 1 and 2. Please order the new OPR and destroy remaining Antenatal 1 and 2 forms. The updated OPR is the fifth revision and replaces the 2005 version. Ontario Perinatal Record (2017 Version) Ontario Perinatal Record User Guide (2018 Version) The new OPR and the development of […]
Ontario Perinatal Record (OPR) Read More »
In Ontario, individuals experiencing early pregnancy complications and loss face numerous challenges in accessing timely, specialized and compassionate care. For many individuals, the emergency department (ED) serves as the primary entry point for care. In 2017, PCMCH, in partnership with Health Quality Ontario and the Champlain Maternal Newborn Regional Program, developed recommendations for ED healthcare
Early Pregnancy Complications and Loss Read More »
Please note: The PCMCH ED Clinical Pathway for Children and Youth with Mental Health Conditions was developed in 2013. The contents of the pathway are valid as of the time of publication. The ED Clinical Pathway for Children and Youth with Mental Health Conditions and the related decision-support tools were developed to guide and support
The overarching goal of the Paediatric Diabetes Network (PDN) is to ensure the best possible health outcomes for children and youth living with diabetes in Ontario. Coordinated by PCMCH since 2013, the PDN is comprised of 35 specialized paediatric diabetes education programs (PDEPs) located primarily in hospitals and community health centres across Ontario. Comprehensive diabetes
Paediatric Diabetes Network Read More »
Please note: The Guideline for Fetal Fibronectin Testing was last updated in 2008 and is valid as of publication. Healthcare providers and the public should verify the information before acting on it. Fetal Fibronectin (fFN) testing helps clinicians to determine if a pregnant person who may be at risk of pre-term birth should be admitted
Fetal Fibronectin Testing Read More »
What was originally developed as a Quality-Based Procedure (QBP) for Hyperbilirubinemia has been revised and updated into a best evidence Clinical Pathway for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks). The contents of this Clinical Pathway Handbook provide guidance to clinicians to ensure all newborns receive bilirubin screening between 24 and 72
Hyperbilirubinemia Screening: Clinical Pathway Handbook Read More »
